B
oth the incidence [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] of and in-hospital mortality [1] [2] [3] [4] [5] [6] [7] [12] [13] [14] [15] from acute myocardial infarctions (AMI), particularly ST-elevation AMI (STEMI), has declined in the United States during the last decade. Regardless of such improvements in disease management, AMI remains the leading cause of death in the United States. 12 Several studies have examined the time trend in the clinical outcome (eg, in-hospital mortality rate, 30-day mortality rate) and costs of care for AMI both at regional and national levels. [1] [2] [3] [4] [5] [6] [7] [8] [9] [13] [14] [15] [16] [17] [18] But to the best of our knowledge, no study has evaluated whether time trend differs by the type of AMI and the intervention the patients received.
In this context, we examined whether the time trends for inhospital mortality and hospital costs for AMI hospitalizations differ by the type of AMI and the intervention performed during hospitalization from 2001 to 2011 using nationally representative data of AMI hospitalizations in the United States.
Methods

Design and Settings
We conducted a serial cross-sectional analysis of hospitalizations from 2001 through 2011, using the Healthcare Cost and Utilization Project (HCUP) Nationwide Impatient Sample (NIS). 19 The NIS is a stratified, single-stage cluster sample, which represents one of the largest all-payer inpatient care data in the United States. NIS samples approximately 8 million hospital discharges per year from hospitals in those states participating in HCUP (eg, NIS 2011-1045 hospitals from 46 states). NIS offers a weight variable and study design variables that enable production of national estimates and their variances of all hospitalizations in the United States during the year. The institutional review boards of Massachusetts General Hospital (Boston, MA) and the University of Tokyo (Tokyo, Japan) approved this study.
Study Participants
All hospitalizations between 2001 and 2011 for patients aged 30 years or older with principal diagnosis of AMI were included in this study. We excluded patients with the hospital length of stay of zero (LOS) because they may have resulted from coding errors, our interest was in ordinary AMI patients who stayed longer than 1 day and the characteristics of the AMI patients with zero LOS (eg, those who were transferred to other institutions or who died within 24 hours of admission) are likely to be different from them, and technically we could not calculate the geometric mean of LOS when the data include zeros. We identified an AMI hospitalization using the International Classification of Diseases-Ninth Revision, Clinical Modification (ICD-9-CM) primary discharge diagnosis code for AMI (ICD-9-CM codes 410.x0 and 410.x1). We excluded ICD-9-CM codes 410.x2 which represents an AMI episode of care following the initial episode (eg, hospital transfers). The primary unit of analysis was a patient hospitalization, counted at discharge. We further classified the hospitalizations into 2 groups by the type of AMI: STEMI and NSTEMI. STEMI was identified by using codes for AMIs of the anterolateral wall (ICD- We considered discharges as having undergone CABG during hospitalization when they had procedure codes of bypass anastomosis for heart revascularization (36.1x). Patients "without intervention" were defined as those having neither of PCI nor CABG during hospitalizations.
Outcome Measures
Primary outcomes of this study were the all-cause in-hospital mortality and costs per hospitalization for AMI. Secondary outcome measures included total costs per hospitalization and hospital length of stay (LOS). Although hospital charges per discharge (physician fees not included) were available in NIS, actual cost data were not available in NIS. Therefore, we used hospital-specific cost-to-charge ratios (CCRs) provided by HCUP and converted charges into costs. 20 When hospitalspecific CCRs were not available, we used group average CCRs instead. The hospital accounting reports collected by the Centers for Medicare and Medicaid Services were used to obtain CCR information. The cases without any CCR information were excluded from the analyses (missing data in <10% of eligible cases), and the data were appropriately reweighted to calculate the national estimates of the costs, as suggested by the HCUP. 20 To facilitate direct comparisons between years for hospital costs, we converted all hospital costs to 2011 US dollars using the Consumer Price Index (CPI).
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Other Variables
We collected information about both patient-and hospital-level characteristics that are associated with the mortality and costs of care, and used them as adjustment variables in our regression models. The collected patient characteristics include age at admission, gender, primary health insurance type, hospitalization source, and comorbidities. We did not include race/ethnicity in our analyses because the data were missing for quite a large portion of units (26% missing in 2001), and the race/ethnicity information in the HCUP data was considered to be missing not at random. Age at admission was categorized by 10 years. Health insurance type was categorized as Medicaid, Medicare, private, or others including the uninsured. Hospitalization source was dichotomized into elective hospitalization or not. Comorbidities were assessed using Clinical Classifications Software (CCS) developed by AHRQ based on the methods by Elixhauser et al, 22 and all comorbidities included in the Elixhauser Comorbidity Index were adjusted except congestive heart failure. The hospital factors include bed size, hospital ownership, hospital region, and a category made of urban/rural distinction and teaching status. With regard to hospital characteristics, bed size was categorized as small, medium, or large based on the number of hospital beds using cut-off points specific to the hospital's region, location, and teaching status. Ownership of the hospital was grouped as government nonfederal, private nonprofit, and private investor-own. Hospital regions consist of Northeast, Midwest, South, and West. Hospital location (urban or rural) and teaching status were jointly categorized as rural, urban non-teaching, and urban teaching.
Statistical Analyses
All analyses used SAS-callable SUDAAN, version 11.0 (Research Triangle Institute, Research Triangle Park, NC) to obtain appropriate variance estimations that accounted for the complex survey sampling design. We calculated AMI hospitalization incidence rates (the number of estimated hospitalizations per 1000 populations) using the population estimates. 23 Poisson regression was used to calculate P values for the trend (P trend ) for the incidence rates. The proportion of STEMI among all AMI hospitalizations was calculated, and the time trend was assessed using the logistic regression models using the year indicator as continuous variable. Weighted estimates of patient and hospital characteristics for each year were described for all AMI discharges, and also separately for STEMI and NSTEMI cases. We also calculated the proportion of cases with PCI and CABG for STEMI and NSTEMI hospitalizations. Logistic regression analyses with year variable used as continuous were used to assess the time trends of the proportions of PCI and CABG use. Next, we examined the trends of in-hospital mortality stratified by the type of AMI and the intervention received. We classified AMI hospitalizations into 6 groups: (1) STEMI with PCI, (2) STEMI with CABG, (3) STEMI without intervention, (4) NSTEMI with PCI, (5) NSTEMI with CABG, and (6) NSTEMI without intervention. We evaluated both unadjusted and adjusted time trend by fitting logistic regression models with the year indicator used as a continuous variable. The patientand hospital-level characteristics adjusted in the evaluation of the adjusted association are listed in Other Variables. In order to account for the clustering of the hospitalizations at hospitallevel, we used generalized estimating equations (GEE) with logistic link function. An exchangeable working correlation structure was selected, as this correlation matrix is most widely used for health data and any permutation is valid. 24 We also examined the temporal trends of hospital costs per hospitalization. Because hospital costs per hospitalization were not normally distributed, we log-transformed the costs per hospitalization, took the average of the logarithmic values, and then back-transformed the average, calculating a geometric mean. We then constructed linear regression models with log-transformed costs as the outcome variable to estimate the percent changes of hospital costs per hospitalization from 2001. We used similar methods for the analysis of the temporal trends of LOS.
We also estimated aggregate national hospital costs on AMI hospitalizations in the United States adjusted for CPI by means of aggregating all the CPI-adjusted costs of all AMI hospitalizations for each year.
Results
From 2001 through 2011, we identified a total of 1 456 154 patient discharges of AMI in the United States, corresponding to a weighted estimate of 7 135 592 discharges. Characteristics of the hospitalized patients with AMI over the 11-year period are presented in Table 1 . There was missing information for each demographic variable as follows: 158 (0.01%) missing gender, 2608 (0.2%) missing payer, 139 082 (9.6%) missing type of admission, 5969 (0.4%) missing bed size and location/teaching status, and 17 799 (1.2%) missing ownership of hospital. There was no missing value with regard to age and hospital region.
Incidence
The overall rate of AMI hospitalizations declined significantly during the study period (4.5 per 1000 populations in 2001 to 3.2 per 1000 populations in 2011; 29% decrease; P trend <0.001, Table 1 ). The proportion of STEMI among AMI hospitalizations also decreased (40.2% in 2001 to 26.9% in 2011; 33% decrease; P trend <0.001). In more recent years, patients hospitalized for AMI were more likely to be male, less likely to be admitted as elective hospitalization, more likely to be admitted to private investor-owned hospitals, and less likely to be admitted to rural hospitals.
Use of PCI and CABG for AMI
The weighted proportion of PCI and CABG use was calculated and shown in Table 2 . During the study period, the use of PCI increased significantly for both the STEMI (75% increase; P trend <0.001) and NSTEMI patients (54% increase; P trend < 0.001). By contrast, the CABG use decreased for both STEMI (39% decrease; P trend <0.001) and NSTEMI (14% decrease; P trend =0.005). Both the proportion of PCI use and the rate of increase in PCI use among STEMI hospitalizations were greater compared with those among NSTEMI hospitalizations.
In-Hospital Mortality
We observed differential time trends of unadjusted in-hospital mortality by the type of AMI and the type of intervention (Table 3) . For STEMI, in-hospital mortality increased among those who did not receive intervention (20% increase, P trend <0.001). On the other hand, the mortality did not change significantly among those who received PCI (3.5% increase, P trend =0.12) or CABG (1.6% decrease, P trend =0.14). Among Table 1 . NSTEMI cases, in-hospital mortality decreased significantly, especially among those who did not receive intervention (29% decrease; P trend <0.001) and those who underwent CABG (41% decrease; P trend <0.001). We did not find a systematic pattern as to the in-hospital mortality among NSTEMI patients who received PCI (16% decrease, P trend =0.29). Table 4 . After controlling for both patient-and hospital-level characteristics, we found that in-hospital mortality improved dramatically among NSTEMI patients regardless of the type of treatments they received. The patient outcomes improved for those patients who received PCI (OR 0.68, 95% CI 0.56 to 0.83), CABG (OR 0.57, 95% CI 0.45 to 0.72), or without intervention (OR 0.61, 95% CI 0.57 to 0.65) ( Table 4 and Figure 1 ). As for STEMI patients, adjusted in-hospital mortality improved for those who received PCI (OR 0.83, 95% CI 0.73 to 0.94), but no significant improvement was seen for those who underwent CABG (OR 0.92, 95% CI 0.72 to 1.19) or those without intervention (OR 0.98, 95% CI 0.88 to 1.09).
Hospital Costs per Hospitalization
The trends in hospital costs were assessed using unadjusted (Table 3 ) and adjusted analyses (Table 5 and Figure 2) . From 2001 to 2011, the hospital costs increased significantly across the subgroups. In the adjusted analyses, the increases in geometric means in 2011 compared with those in 2001 were larger among those with PCI or CABG than among those without intervention. The largest increase was found among STEMI hospitalizations that underwent CABG (20.7% increase; 95% CI, 14.6% to 27.1%).
Length of Stay
The LOS of AMI hospitalizations decreased, especially among those with PCI or those without intervention (eg, STEMI with PCI: 18.3% decrease, 95% CI, À20.5% to À16.1%). The decrease of LOS among those with CABG appeared smaller, and the trend was not statistically significant among NSTEMI hospitalization that underwent CABG (1.2% decrease, 95% CI, À4.5% to 2.3%) ( Table 6 ).
Aggregate National Hospital Costs
The aggregated national hospital costs in the United States are illustrated in Table 7 . After adjusting for the inflation, hospital costs for AMI hospitalizations decreased nationally from $12.4 billion in 2001 to $11.3 billion in 2011 (9% decrease).
Discussion
By using a large, nationally representative database of US hospitalizations from 2001 to 2011, we found that differential time trends of in-hospital mortality and hospital costs by the type of AMI and the type of intervention received. Most notably, adjusted in-hospital mortality declined significantly for NSTEMI regardless of the type of intervention received. In contrast, among STEMI patients, the improvement in inhospital mortality was statistically significant only for those who underwent PCI, and no improvement was observed for those who received CABG or those without any intervention. Hospital costs increased significantly for those who received intervention; the rate of increase in hospital costs was most prominent among those patients who received CABG.
Previous studies have investigated the temporal trends of mortality and hospital costs for AMI patients. An analysis using the Kaiser Permanente Northern California dataset reported that 30-day mortality of NSTEMI patients decreased, whereas the mortality of STEMI patients did not improve. 4 Their sample was not a nationally representative sample of the US population, and the patients who underwent PCI and those who received CABG were not assessed separately. They also did not evaluate the cost data. Movahed et al examined the in-hospital mortality for STEMI and NSTEMI patients using the HCUP NIS datasets, 10,11,15,16 but they did not stratify their analysis by the intervention received. Zhao and colleagues compared hospital costs by the intervention performed using a dataset of commercially insured individuals in the United States. 25 Their data were again not a nationally representative sample, and they did not look into the time trends of hospital costs. To the best of our knowledge, this is the first study showing that the trends of in-hospital mortality and hospital costs differ by type of AMI and intervention received during hospitalization. There are multiple possible reasons for the observed decrease in mortality for NSTEMI without intervention and NSTEMI who underwent CABG. Consistent improvement in primary and secondary prevention of AMI-eg, appropriate prescription of aspirin, b-blockers, and statins 26 -may affect mortality especially among these populations. Alternatively, patients with NSTEMI in more recent study periods may include patients diagnosed only by highly sensitive troponin but with less severe myocardial damage. 4, 14 This could have led to the observed lower mortality in NSTEMI in recent years. Additionally, the indication of CABG for NSTEMI may have changed over time and become highly selective, thereby leading to lower mortality. The increased hospital costs among AMI patients may come from the increasing trend in general medical spending. 27 But the costs of devices and procedures supposedly increased faster than general medical spending considering the prominent increase of costs among those who received intervention. We observed that LOS was shortened for patients with PCI and for patients with CABG (albeit slowly) during the study period; however, the increased costs per unit of intervention might have outweighed the effect of shortened LOS on total costs per hospitalization. At the national level, aggregate national hospital costs for AMI hospitalizations decreased by 9% during the study period (these figures did not include physician fees). The drastically decreased incidence of AMI hospitalizations was mostly offset by the increased hospital costs per hospitalization, especially for AMI with intervention. Curbing the increasing hospital costs per hospitalization may be critical to reduce total health expenditure spent on the treatment of AMI in the United States.
Our study has several limitations. First, as with any studies using administrative data, errors in recording diagnoses are possible. However, HCUP data are shown to be relatively accurate, and widely used to estimate diagnoses, procedures, and healthcare expenditures. 28, 29 Second, due to advances in technology related to PCI, severe AMI cases who would have been treated with CABG a decade ago, are more likely to be treated by PCI in recent years. This does not affect a consistent improvement across the treatment type among NSTEMI patients, but it may explain non-significant improvement in mortality among the STEMI patients who underwent CABG. Third, the HCUP NIS contains discharge-level records, not patient-level records, and thus we were unable to identify multiple hospitalizations for each patient. Fourth, the lack of patient identifiers in the NIS precluded us from using other mortality measures such as 30-day mortality. Previous studies using data from MIDAS in New Jersey found that in-hospital declines in mortality were observed but the post-discharge AMI mortality in fact increased. 30 Our findings cannot be extrapolated to the other outcome measures of the AMI patients, but we believe that the national estimates of the in-hospital mortality over time are valuable information for clinicians and policy makers. Fifth, although we adjusted for both patient-and hospital-level characteristics in evaluating the change in inhospital mortality and hospital costs, there may be unmeasured time-varying confounders. Sixth, the HCUP charges do not include physician fees, thereby leading to underestimation of total costs per AMI hospitalization. However, it is unlikely the proportion of physician fees out of total costs has increased over time differently across the type of AMI and the intervention received; therefore, this may not confound our findings. Lastly, due to the nature of HCUP NIS dataset, costs of care after discharges were unknown. Likosky and colleagues showed more rapid increase in expenditures occurring after discharge using data of fee-for-service Medicare beneficiaries. 31 Additional data and analyses are needed to obtain broader understanding about financial burden of AMI incidence. This study has several important implications. Because AMI continues to be one of the major public health burdens in our healthcare system, the rising spending for AMI hospitalizations should encourage policy makers and health services researchers to develop more cost-effective approaches for the management of AMI. Identification and development of strategies for reducing the costs of AMI hospitalizations accompanied by interventions (ie, PCI and/or CABG) may be an effective approach to reducing the net financial burden of AMI on healthcare systems. For clinicians, the observed decline in the mortality in patients with NSTEMI is encouraging and supports the prior optimism that AMI morbidity and mortality can be prevented.
Conclusions
In summary, using a large nationally representative database of US hospitalizations in 2001-2011, we found that in-hospital 
